Clinical trials on $250,000. Think again. Of course, Koos and BMSN pushed HemaXellerate from IND to FDA approval for human clinical trials. I was excited at the time and thought, "This is it!". The board, like this past week was screaming "To the MOON!" and each time the price dropped, it was due to "stupid people and triggers", but eventually over time as Koos issued millions of more shares and took his salary and kicked out the scientists that had acquired the research, he did nothing with the FDA approval of HemaXellerate. To my knowledge it was never mentioned again. The Koos spun RGBP out of BMSN because of NR2F6 research and followed the same pattern. Scientist pursuing the research and making the discovery was booted out the door once patents were filed and not even given a PR that she was gone. Then from RGBP, he had to spin off 2 more of his own companies where he is the only employee, CEO, COO etc., one to link NR2F6 to the potential for animal treatments and one company for human application, so he can issue millions more shares under each...
Need we say more. Do the DD, please, everyone. NR2F6 may be a very promising component and if Eli Lilly, J&J or someone similar had stepped forward to strike a deal, I'd be all in for the future would not depend on Koos.
But who just licensed it? ONPH, which according to last filing on yahoo did have a bit of revenue back in 2013, but went dark on reporting thereafter, had no cash as of end of 2020, is issuing PRs left and right striking deals with small companies and talking about funding, but with no money, no details and no.... evidence to believe there are anything different from how Koos plays his game. Probably taking fishing trips together on Koos' yacht and came up with the current scheme.
But glad people pushed it from .000 to .06 as I was able to sell my old shares (long and strong - right) above .01 and have some change to invest elsewhere.
News 
Market Data 
Discover 
AI
